Venkata Sabbisetti
Overview
Explore the profile of Venkata Sabbisetti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1356
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schmidt I, Kefalogianni E, Zhao R, Verma A, Sabbisetti V, Rahman M, et al.
Kidney Med
. 2025 Mar;
7(3):100958.
PMID: 40071064
No abstract available.
2.
Xu W, Gaborieau V, Niman S, Mukeria A, Liu X, Maremanda K, et al.
J Clin Oncol
. 2024 May;
42(22):2691-2701.
PMID: 38701382
Purpose: Both clear cell and papillary renal cell carcinomas (RCCs) overexpress kidney injury molecule-1 (KIM-1). We investigated whether plasma KIM-1 (pKIM-1) may be a useful risk stratification tool among patients...
3.
Schmidt I, Colona M, Srivastava A, Yu G, Sabbisetti V, Bonventre J, et al.
Kidney Med
. 2022 Sep;
4(8):100496.
PMID: 36061370
No abstract available.
4.
Sarnak M, Katz R, Ix J, Kimmel P, Bonventre J, Schelling J, et al.
Kidney Int Rep
. 2022 Jul;
7(7):1493-1501.
PMID: 35812266
Introduction: Earlier identification of individuals at high risk of chronic kidney disease (CKD) may facilitate improved risk factor mitigation. Methods: We evaluated the association of novel plasma biomarkers with incident...
5.
Xin C, Lei J, Wang Q, Yin Y, Yang X, Guerrero J, et al.
iScience
. 2021 Oct;
24(10):103193.
PMID: 34703992
Chronic kidney disease (CKD) is associated with substantial morbidity and mortality. We developed a mouse model that mimics human CKD with inflammation, extracellular matrix deposition, tubulointerstitial fibrosis, increased proteinuria, and...
6.
Singh A, Mothi S, Li P, Sabbisetti V, Waikar S, Mc Causland F
Am J Hypertens
. 2021 Jun;
34(11):1203-1208.
PMID: 34192305
Background: Hypertension is common in hemodialysis (HD) patients. Increased blood pressure (BP) variability, particularly higher and lower extremes, is associated with adverse outcomes. We explored the association of endothelin-1 (ET-1),...
7.
Schmidt I, Srivastava A, Sabbisetti V, McMahon G, He J, Chen J, et al.
Am J Kidney Dis
. 2021 Jun;
79(2):231-243.e1.
PMID: 34175376
Rationale & Objective: Plasma kidney injury molecule 1 (KIM-1) is a sensitive marker of proximal tubule injury, but its association with risks of adverse clinical outcomes across a spectrum of...
8.
Xu W, Puligandla M, Halbert B, Haas N, Flaherty K, Uzzo R, et al.
Clin Cancer Res
. 2021 Apr;
27(12):3397-3403.
PMID: 33832947
Purpose: No circulating biomarkers are currently available to identify patients at highest risk of recurrence after nephrectomy for renal cell carcinoma (RCC). Kidney injury molecule-1 (KIM-1) is overexpressed in RCC...
9.
Saha K, Sontheimer E, Brooks P, Dwinell M, Gersbach C, Liu D, et al.
Nature
. 2021 Apr;
592(7853):195-204.
PMID: 33828315
The move from reading to writing the human genome offers new opportunities to improve human health. The United States National Institutes of Health (NIH) Somatic Cell Genome Editing (SCGE) Consortium...
10.
Srivastava A, Schmidt I, Palsson R, Weins A, Bonventre J, Sabbisetti V, et al.
Kidney Int Rep
. 2021 Mar;
6(3):685-694.
PMID: 33732983
Background: Soluble tumor necrosis factor receptor (sTNFR)-1, sTNFR-2, YKL-40, monocyte chemoattractant protein (MCP)-1, and soluble urokinase plasminogen activator receptor (suPAR) have emerged as promising biomarkers of inflammation but have not...